Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
Back to event

Potency Assurance for Cellular and Gene Therapy Products; Guidance for Industry; Availability

By Human Services Department, Food, Health, Drug Administration · Nov 2, 2026, 11:00 PM CST

Read full article at Federal Register
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Potency Assurance for Cellular and Gene Therapy Products." The guidance document provides recommendations to help assure the potency of human cellular therapy or gene therapy (CGT) products at all stages of the product lifecycle. FDA is recommending a comprehensive approach to potency assura

Excerpt shown under fair-use limits. Full text remains with the original publisher.

People in this coverage

Explore their history and attributable record. Being mentioned does not imply endorsement.

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation
INSUFFICIENT CONTEXT
Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

Authority AppealThe statement leverages the FDA's regulatory authority to lend weight to the guidance.

Technical LanguageUses specialized terminology to convey thoroughness and scientific rigor.

Future OrientationFrames the guidance as a roadmap for ongoing and future product development activities.

Context

AI analysis

Missing context

The excerpt does not provide information on how the guidance will be implemented by industry, any timelines for compliance, potential challenges for manufacturers, or the expected impact on product approval processes.

Important context

The guidance is a final FDA document that supersedes a draft issued on December 28, 2023, indicating that the agency has completed its rulemaking process for potency assurance in CGT products.

Opinion vs. reporting

AI analysis

The text is purely informational and does not contain opinion; it reports the FDA's announcement and outlines the content of the guidance.